Underestimating the Value of Drugs that Disrupt the DNA Repair Mechanisms in Cancer Cells.
AstraZeneca’s (AZN) Chief Executive Pascal Soriot said that while DNA damage response was under-recognized by investors, oncologists were already “very excited” by its potential of the drugs targeting DNA repair mechanisms inside cancer cells.
According to AstraZeneca, drugs that disrupt the DNA repair mechanisms inside cancer cells are showing tangible promise for the treatment of various cancers. The firm believes it is well ahead of rivals in the emerging cancer field.
Last year, Nobel Prize for Chemistry were awarded to . . .